These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 22424542

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
    Tzortzaki EG, Georgiou A, Kampas D, Lemessios M, Markatos M, Adamidi T, Samara K, Skoula G, Damianaki A, Schiza S, Tzanakis N, Siafakas NM.
    Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Omalizumab treatment in patients with asthma: summary of Meir Medical Center experience with 47 patients].
    Shitrit D, Talker O, Metabichek A, Yaakovi I.
    Harefuah; 2012 Apr; 151(4):216-9, 254, 253. PubMed ID: 22616149
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The role of omalizumab in the treatment of severe allergic asthma.
    Chapman KR, Cartier A, Hébert J, McIvor RA, Schellenberg RR.
    Can Respir J; 2006 Apr; 13 Suppl B(Suppl B):1B-9B. PubMed ID: 16909166
    [Abstract] [Full Text] [Related]

  • 12. Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma.
    Pelaia G, Gallelli L, Romeo P, Renda T, Busceti MT, Proietto A, Grembiale RD, Marsico SA, Maselli R, Vatrella A.
    Int J Clin Pharmacol Ther; 2011 Dec; 49(12):713-21. PubMed ID: 22122813
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.
    Vennera Mdel C, Pérez De Llano L, Bardagí S, Ausin P, Sanjuas C, González H, Gullón JA, Martínez-Moragón E, Carretero JA, Vera E, Medina JF, Alvarez FJ, Entrenas LM, Padilla A, Irigaray R, Picado C, Spanish Registry.
    J Asthma; 2012 May; 49(4):416-22. PubMed ID: 22443408
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
    Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD, Omalizumab 011 International Study Group.
    Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
    [Abstract] [Full Text] [Related]

  • 19. Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments.
    Pelaia G, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Maselli R.
    Curr Drug Targets; 2015 Apr; 16(2):171-8. PubMed ID: 25523898
    [Abstract] [Full Text] [Related]

  • 20. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
    D'Amato G, Piccolo A, Salzillo A, Noschese P, D'Amato M, Liccardi G.
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.